SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics, Inc. (NYSE American and TASE:LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today reported its third quarter 2026 financial and operating results. The Company will host a conferen…

LCTX

Related stories